Aeterna Zentaris appoints Jurgen Ernst Chairman of the Board of Directors and David J. Mazzo, Ph.D. a Board Member

    QUEBEC CITY, Aug. 14 /CNW Telbec/ - Aeterna Zentaris Inc. (TSX: AEZ;
NASDAQ:   AEZS), a global biopharmaceutical company focused on endocrine therapy
and oncology, today announced the appointments of Jurgen Ernst as Chairman of
the Board of Directors and David J. Mazzo, Ph.D., the Company's President and
Chief Executive Officer (CEO), to its Board of Directors, effective
immediately. Jurgen Ernst has served as Vice Chairman since November 2005 and
succeeds Eric Dupont, Ph.D., who has served as Executive Chairman since
January 2003 and who is stepping down from the Board, also effective today.
    Jurgen Ernst, Chairman of Aeterna Zentaris, stated, "Dr. Dupont's
contributions to the growth and evolution of Aeterna Zentaris have proven to
be invaluable. Since founding the Company in 1991, Dr. Dupont has established
Aeterna Zentaris as a solid, global biopharmaceutical company. He successfully
piloted the spin-off in January 2007 of our former subsidiary, Atrium
Innovations Inc., which was created out of the Company's commercial activities
at the end of 1999. With Aeterna Zentaris emerging earlier this year as a
mature, pure-play global biopharmaceutical company with a rich pipeline, the
implementation of a highly skilled and well experienced new management team,
as well as the Company's secure financial position, Dr. Dupont and the Board
of Directors agreed that now would be an appropriate time for him to retire
from the Board and for the Company to name a new Chairman of the Board. On
behalf of the entire Aeterna Zentaris organization, especially the Board of
Directors, I would like to personally thank Dr. Dupont for his undying
dedication, passion and tenacity over the years, and I am grateful he will
remain a special advisor to the Board to ensure a smooth transition."
    David J. Mazzo, Ph.D., President and CEO of Aeterna Zentaris, added, "We
are very pleased that Jurgen Ernst has agreed to take on additional
responsibilities as Chairman of our Board of Directors. Jurgen is a seasoned
executive, and we will continue to benefit from his 35 years of pharmaceutical
industry experience, specifically corporate development and pharmaceutical
product marketing expertise."
    Dr. Dupont will serve as a special advisor to the Board of Directors of
Aeterna Zentaris until the end of the year.

    About Aeterna Zentaris Inc.

    Aeterna Zentaris Inc. is a global biopharmaceutical company focused on
endocrine therapy and oncology with proven expertise in drug discovery,
development and commercialization.
    News releases and additional information are available at

    Forward-Looking Statements

    This press release contains forward-looking statements made pursuant to
the safe harbor provisions of the U.S. Securities Litigation Reform Act of
1995. Statements that are not historical facts, including statements preceded
by, followed by, or that include the words "believes", "anticipates",
"intends", "plans", "expects", "estimates", "will," "may", "should",
"approximately", and the negative or other variations of those terms or
comparable terminology, are forward-looking statements. Such statements
reflect management's current views, intentions, strategies and plans and are
based on certain assumptions.
    Forward-looking statements involve known and unknown risks and
uncertainties, which could cause the Company's actual results to differ
materially from those in the forward-looking statements. Such risks and
uncertainties include, among others, the ability of Aeterna Zentaris to
implement its business strategies, the availability of funds and resources to
pursue R&D projects, the successful and timely completion of clinical studies,
the ability of Aeterna Zentaris to take advantage of business opportunities in
the pharmaceutical industry, uncertainties related to the regulatory process
and general changes in economic conditions. Investors should consult the
Company's quarterly and annual filings with the Canadian and U.S. securities
commissions for additional information on risks and uncertainties relating to
the forward-looking statements. Investors are cautioned not to rely on these
forward-looking statements. The Company does not undertake to update these
forward-looking statements.

For further information:

For further information: Jenene Thomas, Senior Director, Investor
Relations and Corporate Communications, (418) 655-6420,

Organization Profile

Aeterna Zentaris Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890